Goldman Sachs Call 3250 TDXP 20.0.../ DE000GJ3C3D5 /
| 1/23/2025 8:16:06 AM | Chg.+0.03 | Bid10:00:27 PM | Ask10:00:27 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 4.90EUR | +0.62% | - Bid Size: - |
- Ask Size: - |
TECDAX | 3,250.00 EUR | 6/20/2025 | Call |
GlobeNewswire
7/22/2024
MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire
6/12/2018
Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire
12/13/2016
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire
12/6/2016
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire
12/6/2016
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire
11/28/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire
11/17/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire
11/15/2016
MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire
11/8/2016
Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire
11/3/2016
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire
11/2/2016
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire
10/20/2016
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire
10/17/2016
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire
10/1/2016
MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...